Proteomics International Laboratories Ltd.ASX: PIQ

PromarkerEndo Validation and Refinement Complete

· Issued by Proteomics International Laboratories Ltd. via ASX

Filed with ASX · · 4 pages · English

Summary by 6ix AI

Proteomics International Laboratories Ltd. has completed the refinement and independent validation of its Promarker®Endo blood test for endometriosis, which is designed to aid in the clinical assessment of patients with suspected endometriosis. The company anticipates making Promarker®Endo commercially available in the third quarter of the upcoming fiscal year, pending regulatory requirements.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/promarkerendo-validation-and-refinement-complete

Release

Proteomics International Laboratories Ltd ABN 78 169 979 971 Box 3008, Broadway, Nedlands, WA 6009, Australia T: +61 8 9389 1992 | E: enquiries@proteomicsinternational.com | W: www.proteomicsinternational.com 1/4 Part of the PILL Group ASX Release 13 October...

Proteomics International Laboratories Ltd. on 6ix

In the deck

Earlier from Proteomics International Laboratories

All Proteomics International Laboratories news releases